Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab phase 3 study in HER2-positive advanced gastroesophageal adenocarcinoma
2021-000296-36Phase 3Active
- Sponsor
- Zymeworks Inc.
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC) comparing Zanidatamab + chemotherapy, Zanidatamab + chemotherapy + tislelizumab and Trastuzumab + chemotherapy (3 arms). Primary endpoint: Progression-free survival. Started Jul 2021; status: active.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2021-000296-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000296-36.